{
    "Clinical Trial ID": "NCT00256698",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Fulvestrant + Anastrozole",
        "  Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg",
        "INTERVENTION 2: ",
        "  Anastrozole",
        "Anastrozole 1 mg"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Signed informed consent, postmenopausal females, histological or cytological confirmed oestrogene and/or progesterone (PgR) receptor positive breast cancer, local recurrence or metastasis",
        "Exclusion Criteria:",
        "  Previous systemic endocrine therapy for advanced or recurrent disease; prior fulvestrant therapy",
        "  Premenopausal women"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Time to Progression (TTP)",
        "  RECIST (Response Evaluation Criteria in Solid Tumours) assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009. TTP, time in months to worsen 'progression' according to RECIST criteria. (RECIST is a set of published rules that define when cancer patients improve \"respond\", stay the same \"stable\"or worsen \"progression\" during treatments.",
        "  Time frame: RECIST assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009",
        "Results 1: ",
        "  Arm/Group Title: Fulvestrant + Anastrozole",
        "  Arm/Group Description: Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg",
        "  Overall Number of Participants Analyzed: 258",
        "  Median (Full Range)",
        "  Unit of Measure: months  10.8        (0 to 49.31)",
        "Results 2: ",
        "  Arm/Group Title: Anastrozole",
        "  Arm/Group Description: Anastrozole 1 mg",
        "  Overall Number of Participants Analyzed: 256",
        "  Median (Full Range)",
        "  Unit of Measure: months  10.2        (0 to 54.34)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 40/256 (15.63%)",
        "  Anaemia 1/256 (0.39%)",
        "  Cardiac Failure 3/256 (1.17%)",
        "  Pericardial Effusion 0/256 (0.00%)",
        "  Angina Pectoris 0/256 (0.00%)",
        "  Arrhythmia 0/256 (0.00%)",
        "  Atrial Flutter 0/256 (0.00%)",
        "  Cardiac Arrest 0/256 (0.00%)",
        "  Atrial Fibrillation 1/256 (0.39%)",
        "  Bradycardia 1/256 (0.39%)",
        "  Cardiomyopathy 1/256 (0.39%)",
        "  Myocardial Infarction 1/256 (0.39%)",
        "Adverse Events 2:",
        "  Total: 45/254 (17.72%)",
        "  Anaemia 1/254 (0.39%)",
        "  Cardiac Failure 1/254 (0.39%)",
        "  Pericardial Effusion 2/254 (0.79%)",
        "  Angina Pectoris 1/254 (0.39%)",
        "  Arrhythmia 1/254 (0.39%)",
        "  Atrial Flutter 1/254 (0.39%)",
        "  Cardiac Arrest 1/254 (0.39%)",
        "  Atrial Fibrillation 0/254 (0.00%)",
        "  Bradycardia 0/254 (0.00%)",
        "  Cardiomyopathy 0/254 (0.00%)",
        "  Myocardial Infarction 0/254 (0.00%)"
    ]
}